2026年3月3日星期二,Krystal Biotech (NASDAQ:KRYS)参加了TD Cowen第46届年度医疗保健会议。该公司强调了其战略增长举措,重点关注VYJUVEK销售扩张和管线推进,同时承认在定价谈判和监管流程方面面临的潜在挑战。

Investors are increasingly wary of the rare-disease space, spooked by a regulatory shift.

With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter,” early stage biotechs are rewriting their financing strategies around ...

Puma Biotechnology (NASDAQ:PBYI)于2026年3月2日周一在TD Cowen第46届年度医疗保健会议上进行了展示,重点介绍了其扩大NERLYNX销售和推进临床管线的战略重点。该公司强调了其财务增长以及面临的挑战,包括管理药物副作用和应对监管审批途径。

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...

Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...

When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

After cutting down its pipeline just a few months ago, OSE Immunotherapeutics is at it again, this time reorganizing as Boehringer Ingelheim walks away from the biotech’s metabolic ...

This company develops treatments for rare genetic diseases. It partners with Biogen.

As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...

Transformative Biotech LLC, a Boulder-based company working to develop faster molecular tests for diseases such as COVID-19 and cancer, has appointed Mark Kelleher as executive vice president of ...

This biotech powerhouse could maintain its strength for the long term.